Johnson and Johnson subsidiary to team up with University of Queensland spin-out to treat rheumatoid arthritis.
Dendright Pty, a biotech spin-out from the University of Queensland (UQ), has announced a collaboration with Johnson and Johnson subsidiary Janssen Biotech to tackle rheumatoid arthritis.
As part of the deal, the two will work together to move a new treatment, based on research from UQ’s Diamantina Institute, for the condition towards Phase I clinical trials. The deal is part of a developing relationship between the two firms after Janssen provided Dendright with seed financing last year.
The treatment differs from current treatments by dealing with the underlying causes of the treatment as opposed to the inflammatory symptoms it generates.
Ranjeny Thomas, the UQ professor behind the research, said: “We are very pleased to be continuing and strengthening our strategic collaboration with Janssen, focussing on the application of our platform technology towards rheumatoid arthritis. Our goal is to provide rheumatoid arthritis patients with a new, safe therapy for the management of their disease, with the possibility of disease prevention in the future.”
